http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018203194-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87a91adf7ca06ee11faf526374720aff |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61fe10dccac06b04bebf83edaa84df7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_901030ca2ca54955f0172bfe2cd1c78c |
| publicationDate | 2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2018203194-A1 |
| titleOfInvention | Legumain activated doxorubicin derivative as well as preparation method and application thereof |
| abstract | The present invention discloses doxorubicin derivatives for targeted activation by legumain, its preparation method and use. The doxorubicin derivatives are obtained by 5 condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: r H H 0 0 OH ,N--R3-An--& 4-Rs-R - "OH compounds A and B have the following structures, respectively: OCHS) OH 0 ,NH 2 R3-Asn-R4-R5-R6 "OH 10 Compound A Compound B wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is 0 , wherein n=1-20; or 0 , wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1 -C20 fatty 15 hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be use to prepare an anti-tumor drug. |
| priorityDate | 2012-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.